ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2521

DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort

Victor Pimentel-Quiroz1, Alvaro Oyarce-Calderón2, Allison Figueroa-Sánchez3, Leonor León-Yaurimucha3, Rocío Gamboa-Cárdenas4, Zoila Rodríguez-Bellido5, Risto Perich-Campos6, Graciela Alarcón7 and Manuel Ugarte-Gil8, 1Universidad Científica del Sur, San Isidro, Peru, 2Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Peru, 3Universidad Científica del Sur, Lima, Peru, 4Universidad Científica del Sur, Lima, Peru, 5Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, 6Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, 7The University of Alabama at Birmingham, Oakland, CA, 8Universidad Cientifica del Sur, Lima, Peru

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2504–2523) Vasculitis – ANCA-Associated Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The DANGER score can predict mortality in patients with ANCA-associated vasculitis (AAV) with glomerulonephritis (GN). However, this score has not been widely validated and, moreover, there is no evidence of its use in AAV patients without GN. The aim of this study was to evaluate the performance of this score in AAV patients with or without GN from a Latin American cohort.

Methods: This was a medical records review study which included patients from the Almenara Vasculitis Cohort who had at least one visit between January 1990 and December 2024. Diagnosis of either microscopic polyangiitis (MPA) or granulomatosis with polyangiitis were included. Mortality was determined as the vital status according to the official information from the Peruvian Department of Health. Sociodemographic and clinical features were obtained. The DANGER score includes four variables: age at diagnosis, history of hypertension or cardiac disease, and creatinine and hemoglobin levels at diagnosis. This score stratifies the risk of mortality in low, intermediate and high. Unadjusted and adjusted Cox regression models were done to assess the impact of the DANGER score. The model was adjusted for age at diagnosis, gender and type of diagnosis.

Results: Two hundred twenty-five patients were enrolled; most of them were female [154 (68.4%)]. Mean of age and time of follow-up were 59.4 (12.6) and 7.7 (7.1) years, respectively. MPA was the most frequent diagnosis [177 (78.7%)]. During the follow-up, 110 (48.9%) patients died. As to the DANGER score, 105 (46.7%), 113 (50.2%) and 7 (3.1%) patients had low, intermediate and high risk of mortality, respectively. Furthermore, each risk category was predictive of mortality in the unadjusted and adjusted analyses (Table 1). Overall survival according to the stratification is depicted in Figure 1.

Conclusion: The DANGER score had good performance in AAV patients with or without GN in a Latin American cohort. More studies in other populations are necessary to validate these findings.

Supporting image 1Table 1. Unadjusted and adjusted analyses.

Supporting image 2Figure 1. Kaplan-Meier plot of survival according to categories by the DANGER score.


Disclosures: V. Pimentel-Quiroz: Biopas, 6, Pfizer, 6, Roche, 6, technofarm, 6; A. Oyarce-Calderón: None; A. Figueroa-Sánchez: None; L. León-Yaurimucha: None; R. Gamboa-Cárdenas: None; Z. Rodríguez-Bellido: None; R. Perich-Campos: None; G. Alarcón: None; M. Ugarte-Gil: AstraZeneca, 1, 6, Ferrer, 1, GlaxoSmithKlein(GSK), 6, Janssen, 5, technofarma, 1.

To cite this abstract in AMA style:

Pimentel-Quiroz V, Oyarce-Calderón A, Figueroa-Sánchez A, León-Yaurimucha L, Gamboa-Cárdenas R, Rodríguez-Bellido Z, Perich-Campos R, Alarcón G, Ugarte-Gil M. DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/danger-score-as-predictor-of-mortality-in-anca-associated-vasculitis-with-or-without-glomerulonephritis-data-from-the-almenara-vasculitis-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/danger-score-as-predictor-of-mortality-in-anca-associated-vasculitis-with-or-without-glomerulonephritis-data-from-the-almenara-vasculitis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology